Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Januar 2022 18:54 ET | Quelle: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – NRXP; NRXPW

NEW YORK, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP; NRXPW) and...
31. Januar 2022 11:00 ET | Quelle: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)

LOS ANGELES, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 21, 2022 deadline to file a lead plaintiff motion in the class action...
25. Januar 2022 13:08 ET | Quelle: Wolf Haldenstein Adler Freeman & Herz LLP

NRX PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed against NRx Pharmaceuticals, Inc. in the United States District Court for the District of Delaware

NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against NRx Pharmaceuticals, Inc....
24. Januar 2022 10:50 ET | Quelle: Bronstein, Gewirtz & Grossman, LLC

NRXP; NRXPW Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: March 21, 2022

NEW YORK, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NRx Pharmaceuticals,...
23. Januar 2022 21:00 ET | Quelle: Bragar Eagel & Squire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First Solar, eHealth, and NRx Pharmaceuticals and Encourages Investors to Contact the Firm

NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
23. Januar 2022 17:01 ET | Quelle: Robbins Geller Rudman & Dowd LLP

NRXP ALERT: Robbins Geller Rudman & Dowd LLP Announces that NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Jan. 23, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP; NRXPW) securities...
23. Januar 2022 10:57 ET | Quelle: Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NRx Pharmaceuticals, Inc, of Class Action Lawsuit and Upcoming Deadline – NRXP; NRXPW

NEW YORK, Jan. 23, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP; NRXPW) and...
19. Januar 2022 19:00 ET | Quelle: Johnson Fistel, LLP

(NRXP; NRXPW) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading NRx Pharmaceuticals Class Action Lawsuit

SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of NRx Pharmaceuticals, Inc....
18. Januar 2022 18:18 ET | Quelle: Pomerantz LLP

Pomerantz Law Firm Announces the Filing of a Class Action Against NRx Pharmaceuticals, Inc, and Certain Officers – NRXP; NRXPW

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) (NASDAQ: NRXP; NRXPW) and...
18. Januar 2022 06:48 ET | Quelle: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments

ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded...

Vorherige Seite

Nächste Seite